# Jaffer A. Ajani

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jaffer-a-ajani/

## Facts

| Field | Value |
| --- | --- |
| Citations | 111,754 |
| Field | Gastric Cancer Management and Outcomes |
| h-index | 152 |
| i10-index | 731 |
| Last Known Institution | The University of Texas MD Anderson Cancer Center |
| OpenAlex ID | https://openalex.org/A5044064524 |
| ORCID iD | https://orcid.org/0000-0001-9946-0629 |
| Works | 1,735 |

## Researcher papers

Showing 12 of 14.

- [Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial](https://scholariq.org/papers/ramucirumab-plus-paclitaxel-versus-placebo-plus-paclitaxel-in-patients-with/)
- [Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer](https://scholariq.org/papers/adjuvant-nivolumab-in-resected-esophageal-or-gastroesophageal-junction-cancer/)
- [Chemotherapy Followed by Surgery Compared with Surgery Alone for Localized Esophageal Cancer](https://scholariq.org/papers/chemotherapy-followed-by-surgery-compared-with-surgery-alone-for-localized/)
- [Fluorouracil, Doxorubicin, and Streptozocin in the Treatment of Patients With Locally Advanced and Metastatic Pancreatic Endocrine Carcinomas](https://scholariq.org/papers/fluorouracil-doxorubicin-and-streptozocin-in-the-treatment-of-patients-with/)
- [ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade](https://scholariq.org/papers/arid1a-deficiency-promotes-mutability-and-potentiates-therapeutic-antitumor/)
- [Long-Term Results of RTOG Trial 8911 (USA Intergroup 113): A Random Assignment Trial Comparison of Chemotherapy Followed by Surgery Compared With Surgery Alone for Esophageal Cancer](https://scholariq.org/papers/long-term-results-of-rtog-trial-8911-usa-intergroup-113-a-random-assignment/)
- [Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma](https://scholariq.org/papers/nivolumab-combination-therapy-in-advanced-esophageal-squamous-cell-carcinoma/)
- [Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance](https://scholariq.org/papers/pan-cancer-t-cell-atlas-links-a-cellular-stress-response-state-to-immunotherapy/)
- [Octreotide Acetate Long-Acting Formulation Versus Open-Label Subcutaneous Octreotide Acetate in Malignant Carcinoid Syndrome](https://scholariq.org/papers/octreotide-acetate-long-acting-formulation-versus-open-label-subcutaneous/)
- [Intrinsic Subtypes of Gastric Cancer, Based on Gene Expression Pattern, Predict Survival and Respond Differently to Chemotherapy](https://scholariq.org/papers/intrinsic-subtypes-of-gastric-cancer-based-on-gene-expression-pattern-predict/)
- [Effect of operative volume on morbidity, mortality, and hospital use after esophagectomy for cancer](https://scholariq.org/papers/effect-of-operative-volume-on-morbidity-mortality-and-hospital-use-after/)
- [Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study](https://scholariq.org/papers/tislelizumab-versus-chemotherapy-as-second-line-treatment-for-advanced-or/)

## Researcher topics

- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Gastrointestinal Tumor Research and Treatment](https://scholariq.org/topics/gastrointestinal-tumor-research-and-treatment/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Researcher university

- [The University of Texas MD Anderson Cancer Center](https://scholariq.org/institutions/the-university-of-texas-md-anderson-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.